Phase II multicenter study of second-line FOLFIRI plus cetuximab (FLIER) in patients with KRAS wild-type metastatic colorectal cancer: Final analysis of survival and additional analysis of BRAF, PI3CA mutations.

Published 2017 View Full Article

Authors

Keywords

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 30, Issue 4_suppl, Pages 481-481

Publisher

American Society of Clinical Oncology (ASCO)

Online

2017-02-24

DOI

10.1200/jco.2012.30.4_suppl.481

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF CLINICAL ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.